Cash, cash equivalents and marketable securities were $621.2 million as of June 30, 2025, compared to $681.4 million as of March 31, 2025. Based on current operating plans, Apogee expects that its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into the first quarter of 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Analysts Spot 3 Strong Buy Russell 2000 Stocks with 100% Upside
- Apogee Therapeutics price target raised to $115 from $100 at BTIG
- 3 Best Stocks to Buy Now, 7/9/2025, According to Top Analysts
- Promising Phase II Results for Apogee Therapeutics’ APG777 Drive Buy Rating and $89 Price Target
- Promising Potential of Apogee Therapeutics’ APG777 in Atopic Dermatitis Market Drives Buy Rating and Increased Price Target